| Residential College | false |
| Status | 即將出版Forthcoming |
| Anti-TNF therapy in the treatment of systemic autoinflammatory diseases: the responses of innate immune cells | |
Shuyi Wang1; Rufei Xiao1; Yibo Chen1; Yishan Ye2; Tianzhen He3; Yang Yang1; Xin Chen1 ; Chon-Kit Chou1
| |
| 2025-01 | |
| Source Publication | Journal of Leukocyte Biology
 |
| Abstract | Abstract Systemic autoinflammatory diseases (SAIDs) are rare conditions resulting from innate immune system dysregulation, culminating in repetitive bouts of systemic inflammation without the presence of external or self-antigens. Most SAIDs are associated with mutations in genes affecting the innate immune response. Tumor necrosis factor (TNF) is a central player in the pathogenesis of numerous chronic inflammatory disorders, and anti-TNF therapy is widely used in the clinical management of SAIDs. TNF inhibitors block the interaction of TNF with its two receptors, TNF receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). These inhibitors primarily target soluble TNF (sTNF), which mainly binds to TNFR1, exerting anti-inflammatory effects. Interestingly, TNF inhibitors also affect transmembrane TNF (tmTNF), which engages TNFR2 to initiate reverse signaling. This reverse signaling can activate innate immune cells, prevent 1 apoptosis, or paradoxically inhibit the production of pro-inflammatory cytokines. TNF inhibitors also promote the release of soluble TNFR2 (sTNFR2), which neutralizes circulating TNF. Some agents targeting TNFR2 can even act as agonists, triggering reverse signaling by binding to tmTNF. While effective, prolonged use of TNF inhibitors may cause significant side effects due to the widespread expression and pleiotropic functions of TNF receptors. More thoroughly understanding of the mechanisms underlying the action of TNF inhibitors is required to develop more effective and safer treatment for SAIDs. This article reviews current studies on the role of the innate immune system in SAID pathogenesis, the impact of anti-TNF therapy on innate immune cells, and perspectives on developing improved agents targeting TNF or its receptors. |
| Keyword | Keywords: Systemic Autoinflammatory Diseases Anti-tnf Therapy Innate Immune Cells Autoinflammation Tnf Inhibitors: Tnfr1 Tnfr2 |
| Language | 英語English |
| Document Type | Journal article |
| Collection | Institute of Chinese Medical Sciences |
| Corresponding Author | Xin Chen; Chon-Kit Chou |
| Affiliation | 1.Institute of Chinese Medical Sciences, State Key Laboratory of Quality Research in 8 Chinese Medicine, University of Macau, Macau, 999078, P. R. China 2.Bone Marrow Transplantation Center, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310058, China 3.Institute of special environmental medicine, Nantong University, Nantong, 226019, China. |
| First Author Affilication | Institute of Chinese Medical Sciences |
| Corresponding Author Affilication | Institute of Chinese Medical Sciences |
| Recommended Citation GB/T 7714 | Shuyi Wang,Rufei Xiao,Yibo Chen,et al. Anti-TNF therapy in the treatment of systemic autoinflammatory diseases: the responses of innate immune cells[J]. Journal of Leukocyte Biology, 2025. |
| APA | Shuyi Wang., Rufei Xiao., Yibo Chen., Yishan Ye., Tianzhen He., Yang Yang., Xin Chen., & Chon-Kit Chou (2025). Anti-TNF therapy in the treatment of systemic autoinflammatory diseases: the responses of innate immune cells. Journal of Leukocyte Biology. |
| MLA | Shuyi Wang,et al."Anti-TNF therapy in the treatment of systemic autoinflammatory diseases: the responses of innate immune cells".Journal of Leukocyte Biology (2025). |
| Files in This Item: | There are no files associated with this item. | |||||
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment